Literature DB >> 26956246

Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Lawrence Toll1, Michael R Bruchas2, Girolamo Calo'2, Brian M Cox2, Nurulain T Zaveri2.   

Abstract

The NOP receptor (nociceptin/orphanin FQ opioid peptide receptor) is the most recently discovered member of the opioid receptor family and, together with its endogenous ligand, N/OFQ, make up the fourth members of the opioid receptor and opioid peptide family. Because of its more recent discovery, an understanding of the cellular and behavioral actions induced by NOP receptor activation are less well developed than for the other members of the opioid receptor family. All of these factors are important because NOP receptor activation has a clear modulatory role on mu opioid receptor-mediated actions and thereby affects opioid analgesia, tolerance development, and reward. In addition to opioid modulatory actions, NOP receptor activation has important effects on motor function and other physiologic processes. This review discusses how NOP pharmacology intersects, contrasts, and interacts with the mu opioid receptor in terms of tertiary structure and mechanism of receptor activation; location of receptors in the central nervous system; mechanisms of desensitization and downregulation; cellular actions; intracellular signal transduction pathways; and behavioral actions with respect to analgesia, tolerance, dependence, and reward. This is followed by a discussion of the agonists and antagonists that have most contributed to our current knowledge. Because NOP receptors are highly expressed in brain and spinal cord and NOP receptor activation sometimes synergizes with mu receptor-mediated actions and sometimes opposes them, an understanding of NOP receptor pharmacology in the context of these interactions with the opioid receptors will be crucial to the development of novel therapeutics that engage the NOP receptor. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26956246      PMCID: PMC4813427          DOI: 10.1124/pr.114.009209

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  371 in total

1.  Partial loss of tolerance liability to morphine analgesia in mice lacking the nociceptin receptor gene.

Authors:  H Ueda; T Yamaguchi; S Tokuyama; M Inoue; M Nishi; H Takeshima
Journal:  Neurosci Lett       Date:  1997-11-21       Impact factor: 3.046

Review 2.  Ziconotide: a clinical update and pharmacologic review.

Authors:  Jason E Pope; Timothy R Deer
Journal:  Expert Opin Pharmacother       Date:  2013-03-28       Impact factor: 3.889

3.  Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair.

Authors:  Celia Goeldner; Will Spooren; Jürgen Wichmann; Eric P Prinssen
Journal:  Psychopharmacology (Berl)       Date:  2012-01-18       Impact factor: 4.530

4.  Modulation of Ca2+ channel currents of acutely dissociated rat periaqueductal grey neurons.

Authors:  M Connor; M J Christie
Journal:  J Physiol       Date:  1998-05-15       Impact factor: 5.182

5.  Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice.

Authors:  A Rizzi; R Bigoni; G Marzola; R Guerrini; S Salvadori; D Regoli; G Calo'
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-02       Impact factor: 3.000

6.  Orphanin FQ/nociceptin activates nuclear factor kappa B.

Authors:  Courtney L Donica; Vanessa I Ramirez; Hibah O Awwad; Nurulain T Zaveri; Lawrence Toll; Kelly M Standifer
Journal:  J Neuroimmune Pharmacol       Date:  2011-05-06       Impact factor: 4.147

7.  Up-regulation of ORL-1 receptors in spinal tissue of allodynic rats after sciatic nerve injury.

Authors:  Luca Briscini; Laura Corradini; Ennio Ongini; Rosalia Bertorelli
Journal:  Eur J Pharmacol       Date:  2002-06-28       Impact factor: 4.432

8.  Effects of receptor density on Nociceptin/OrphaninFQ peptide receptor desensitisation: studies using the ecdysone inducible expression system.

Authors:  T A Barnes; J McDonald; D J Rowbotham; T L Duarte; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-25       Impact factor: 3.000

9.  Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone.

Authors:  A Kuzmin; J Sandin; L Terenius; S O Ogren
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

10.  The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510).

Authors:  Geoffrey B Varty; Sherry X Lu; Cynthia A Morgan; Mary E Cohen-Williams; Robert A Hodgson; April Smith-Torhan; Hongtao Zhang; Ahmad B Fawzi; Michael P Graziano; Ginny D Ho; Julius Matasi; Deen Tulshian; Vicki L Coffin; Galen J Carey
Journal:  J Pharmacol Exp Ther       Date:  2008-05-20       Impact factor: 4.030

View more
  94 in total

1.  BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.

Authors:  Norikazu Kiguchi; Huiping Ding; Gerta Cami-Kobeci; Devki D Sukhtankar; Paul W Czoty; Heather B DeLoid; Fang-Chi Hsu; Lawrence Toll; Stephen M Husbands; Mei-Chuan Ko
Journal:  Br J Anaesth       Date:  2019-03-01       Impact factor: 9.166

Review 2.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 3.  Insights into the function of opioid receptors from molecular dynamics simulations of available crystal structures.

Authors:  Kristen A Marino; Yi Shang; Marta Filizola
Journal:  Br J Pharmacol       Date:  2017-04-12       Impact factor: 8.739

4.  A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.

Authors:  Huiping Ding; Norikazu Kiguchi; Dennis Yasuda; Pankaj R Daga; Willma E Polgar; James J Lu; Paul W Czoty; Shiroh Kishioka; Nurulain T Zaveri; Mei-Chuan Ko
Journal:  Sci Transl Med       Date:  2018-08-29       Impact factor: 17.956

5.  Modulation of opioid receptor affinity and efficacy via N-substitution of 9β-hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and computer simulation study.

Authors:  Phong M Truong; Sergio A Hassan; Yong-Sok Lee; Theresa A Kopajtic; Jonathan L Katz; Aaron M Chadderdon; John R Traynor; Jeffrey R Deschamps; Arthur E Jacobson; Kenner C Rice
Journal:  Bioorg Med Chem       Date:  2017-03-01       Impact factor: 3.641

6.  Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys.

Authors:  Shawn M Flynn; Phillip M Epperly; April T Davenport; Gerta Cami-Kobeci; Stephen M Husbands; Mei-Chuan Ko; Paul W Czoty
Journal:  Neuropsychopharmacology       Date:  2019-04-10       Impact factor: 7.853

7.  Gγ7 proteins contribute to coupling of nociceptin/orphanin FQ peptide (NOP) opioid receptors and voltage-gated Ca(2+) channels in rat stellate ganglion neurons.

Authors:  Saifeldin Mahmoud; Mohamed Farrag; Victor Ruiz-Velasco
Journal:  Neurosci Lett       Date:  2016-05-26       Impact factor: 3.046

8.  Nociceptin Receptors Upregulated in Cocaine Use Disorder: A Positron Emission Tomography Imaging Study Using [11C]NOP-1A.

Authors:  Rajesh Narendran; Savannah Tollefson; Michael L Himes; Jennifer Paris; Brian Lopresti; Roberto Ciccocioppo; N Scott Mason
Journal:  Am J Psychiatry       Date:  2019-05-06       Impact factor: 18.112

9.  NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine.

Authors:  Victor A D Holanda; Wilton B Santos; Laila Asth; Remo Guerrini; Girolamo Calo'; Chiara Ruzza; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2018-08-25       Impact factor: 4.530

10.  Blockade of NOP receptor modulates anxiety-related behaviors in mice exposed to inescapable stress.

Authors:  Aldemara I Silva; Victor A D Holanda; Joaquim G Azevedo Neto; Edilson D Silva Junior; Vanessa P Soares-Rachetti; Girolamo Calo; Chiara Ruzza; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2020-02-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.